Literature DB >> 2374235

Endoscopic correction of vesicoureteral reflux: our experience with 115 ureters.

A Farkas1, E Z Moriel, S Lupa.   

Abstract

Endoscopic subureteral injection of polytetrafluoroethylene was performed in 115 ureters to correct vesicoureteral reflux. We treated primary reflux in 84 single ureters, 16 duplex ureters and 4 megaureters (grade V), and secondary reflux in 11 ureters associated with neurogenic bladder, uncapped ureteroceles and failed ureteroneocystostomy. Followup evaluation consisted of a voiding cystourethrogram, which was done in the operating room immediately after the endoscopic procedure, ultrasound 1 month postoperatively, and a diethylenetriaminepentaacetic acid renal isotope scan and repeat voiding cystourethrogram 6 months after injection. Grades II to IV primary reflux involving single as well as duplex ureters resolved in 94% and 82%, respectively, of the cases after 1 injection and in 98% and 93% of the cases after 2 or more injections. The severely and chronically dilated ureters did not respond to the treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2374235     DOI: 10.1016/s0022-5347(17)39515-0

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  3 in total

1.  Endoscopic correction of complex cases of vesicoureteral reflux utilizing Vantris as a new non-biodegradable tissue-augmenting substance.

Authors:  Boris Chertin; Wael Abu Arafeh; Stanislav Kocherov
Journal:  Pediatr Surg Int       Date:  2014-04       Impact factor: 1.827

2.  Subureteral collagen injection versus antireflux surgery in primary vesico-ureteral reflux grade III.

Authors:  N Gordjani; A Frankenschmidt; L B Zimmerhackl; M Brandis
Journal:  Eur J Pediatr       Date:  1996-06       Impact factor: 3.183

3.  Reflux nephropathy and hypertension: correlation with the progression of renal damage.

Authors:  Giuliana Lama; Michele Adolfo Tedesco; Luisa Graziano; Elvira Calabrese; Carolina Grassia; Francesco Natale; Giuseppe Pacileo; Pier Francesco Rambaldi; Maria Esposito-Salsano
Journal:  Pediatr Nephrol       Date:  2003-02-26       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.